GlassScriptPhysician profile
Scott P Leary
NPI 1417085978
$351,789.19
in general payments reported to CMS, 2019-2025
22 companies · $97K in 2025
The $97K reported for 2025 was more than what 97% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $43K · 2021: $65K · 2022: $42K · 2023: $25K · 2024: $50K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $153K · Consulting Fee: $17K · Food and Beverage: $2,050 · Travel and Lodging: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $153,253.20 |
| Consulting Fee | $17,000.00 |
| Food and Beverage | $2,049.53 |
| Travel and Lodging | $283.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medacta USA, INC. | $125,103.01 | 2019-2025 | Must |
| Kyocera Medical Technologies, INC. | $118,389.21 | 2019-2025 | |
| Aesculap Implant Systems, LLC | $61,430.68 | 2019-2025 | Quintex |
| Integrity Implants INC. | $22,600.23 | 2019-2022 | |
| Surgalign Spine Technologies, INC. | $15,225.94 | 2019-2021 | |
| Integrity Implants INC. Dba Accelus | $4,882.16 | 2023-2024 | Linesider |
| Arteriocyte Medical Systems, INC. | $1,664.39 | 2019-2024 | Magellan |
| Xtant Medical INC | $822.71 | 2024-2025 | |
| Centinel Spine, LLC | $468.87 | 2019-2025 | Prodisc C Vivo |
| Nexxt Spine LLC | $263.92 | 2025 | Nexxt Spine Technology |
| Innovasis INC | $252.83 | 2022 | |
| Cerapedics INC. | $139.52 | 2022 | |
| Si-Bone, INC. | $121.05 | 2021 | |
| Woven Orthopedic Technologies, LLC | $120.09 | 2024 | |
| Medical Device Business Services, INC. | $100.80 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $66.32 | 2024 | Intellis Adaptivestim |
| Kci USA, INC. | $61.93 | 2021-2023 | Prevena |
| Portola Pharmaceuticals, LLC | $24.02 | 2020 | |
| Smith+Nephew, INC. | $19.45 | 2025 | Collagenase Santyl |
| Aesculap, INC. | $16.00 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.68 | 2020 | |
| Biocomposites INC | $4.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,500,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Leary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.